Long-acting bronchodilators have an extended ... possible clinical effects and may not target all components of COPD. Another bronchodilator, theophylline, has proven efficacy and an anti ...

Background: Some studies have suggested that use of long-acting β 2-agonists (LABAs) leads to an increased risk for adverse events in patients with stable COPD. The purpose of this review was to ...

Bronchodilator therapy forms the mainstay of treatment for people with COPD. Bronchodilators work by altering the airways’ smooth muscle tone, leading to widening of the airways, which ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

A total of 2,802 patients with COPD were randomised 1:1 to receive ... and could include single or dual long-acting bronchodilator therapy, inhaled corticosteroid either alone or in combination ...

The right treatment plan can help you control your COPD symptoms and avoid exacerbations (flareups). These include shortness ...

Current treatments for COPD include one anti-inflammatory medication and two long-acting medications that are also bronchodilators. These treatments are often taken in combination, depending on ...

The Bronchodilator Drugs market in South Korea is forecasted to achieve a revenue of US$0.37bn in 2024. It is expected to exhibit a compound annual growth rate (CAGR) of 3.99% from 2024 to 2029 ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...